Multicenter, Randomized, Double-Blind Study of Ceftobiprole [medocaril] Versus Comparators in the Treatment of Patients With Fever and Neutropenia.

Trial Profile

Multicenter, Randomized, Double-Blind Study of Ceftobiprole [medocaril] Versus Comparators in the Treatment of Patients With Fever and Neutropenia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Ceftobiprole medocaril (Primary) ; Cefepime; Vancomycin
  • Indications Bacterial infections; Febrile neutropenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Basilea Pharmaceutica; Janssen Research & Development
  • Most Recent Events

    • 07 Aug 2012 Additional trial locations (Belgium and Hungery), Janssen-Cilag as sponsor and lead trial centre added as reported by European Clinical Trials Database record.
    • 31 Jul 2012 Company (Basilea Pharmaceutica) added as an association and lead cantre as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Actual end date (1 Jan 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top